These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22971958)

  • 1. Low lysine diet in glutaric aciduria type I--effect on anthropometric and biochemical follow-up parameters.
    Boy N; Haege G; Heringer J; Assmann B; Mühlhausen C; Ensenauer R; Maier EM; Lücke T; Hoffmann GF; Müller E; Burgard P; Kölker S
    J Inherit Metab Dis; 2013 May; 36(3):525-33. PubMed ID: 22971958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementary dietary treatment using lysine-free, arginine-fortified amino acid supplements in glutaric aciduria type I - A decade of experience.
    Kölker S; Boy SP; Heringer J; Müller E; Maier EM; Ensenauer R; Mühlhausen C; Schlune A; Greenberg CR; Koeller DM; Hoffmann GF; Haege G; Burgard P
    Mol Genet Metab; 2012 Sep; 107(1-2):72-80. PubMed ID: 22520952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision.
    Boy N; Mühlhausen C; Maier EM; Heringer J; Assmann B; Burgard P; Dixon M; Fleissner S; Greenberg CR; Harting I; Hoffmann GF; Karall D; Koeller DM; Krawinkel MB; Okun JG; Opladen T; Posset R; Sahm K; Zschocke J; Kölker S;
    J Inherit Metab Dis; 2017 Jan; 40(1):75-101. PubMed ID: 27853989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inconsistencies in the Nutrition Management of Glutaric Aciduria Type 1: An International Survey.
    Bernstein L; Coughlin CR; Drumm M; Yannicelli S; Rohr F
    Nutrients; 2020 Oct; 12(10):. PubMed ID: 33081139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutaric acidemia type 1: Treatment and outcome of 168 patients over three decades.
    Strauss KA; Williams KB; Carson VJ; Poskitt L; Bowser LE; Young M; Robinson DL; Hendrickson C; Beiler K; Taylor CM; Haas-Givler B; Hailey J; Chopko S; Puffenberger EG; Brigatti KW; Miller F; Morton DH
    Mol Genet Metab; 2020 Nov; 131(3):325-340. PubMed ID: 33069577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx.
    Strauss KA; Brumbaugh J; Duffy A; Wardley B; Robinson D; Hendrickson C; Tortorelli S; Moser AB; Puffenberger EG; Rider NL; Morton DH
    Mol Genet Metab; 2011; 104(1-2):93-106. PubMed ID: 21820344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic modulation of cerebral L-lysine metabolism in a mouse model for glutaric aciduria type I.
    Sauer SW; Opp S; Hoffmann GF; Koeller DM; Okun JG; Kölker S
    Brain; 2011 Jan; 134(Pt 1):157-70. PubMed ID: 20923787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary practices in glutaric aciduria type 1 over 16 years.
    Gokmen-Ozel H; MacDonald A; Daly A; Ashmore C; Preece MA; Hendriksz C; Vijay S; Chakrapani A
    J Hum Nutr Diet; 2012 Dec; 25(6):514-9. PubMed ID: 22845646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of interventional and non-interventional variables on anthropometric long-term development in glutaric aciduria type 1: A national prospective multi-centre study.
    Märtner EMC; Maier EM; Mengler K; Thimm E; Schiergens KA; Marquardt T; Santer R; Weinhold N; Marquardt I; Das AM; Freisinger P; Grünert SC; Vossbeck J; Steinfeld R; Baumgartner MR; Beblo S; Dieckmann A; Näke A; Lindner M; Heringer-Seifert J; Lenz D; Hoffmann GF; Mühlhausen C; Ensenauer R; Garbade SF; Kölker S; Boy N
    J Inherit Metab Dis; 2021 May; 44(3):629-638. PubMed ID: 33274439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.
    Boy N; Mühlhausen C; Maier EM; Ballhausen D; Baumgartner MR; Beblo S; Burgard P; Chapman KA; Dobbelaere D; Heringer-Seifert J; Fleissner S; Grohmann-Held K; Hahn G; Harting I; Hoffmann GF; Jochum F; Karall D; Konstantopoulous V; Krawinkel MB; Lindner M; Märtner EMC; Nuoffer JM; Okun JG; Plecko B; Posset R; Sahm K; Scholl-Bürgi S; Thimm E; Walter M; Williams M; Vom Dahl S; Ziagaki A; Zschocke J; Kölker S
    J Inherit Metab Dis; 2023 May; 46(3):482-519. PubMed ID: 36221165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifactorial modulation of susceptibility to l-lysine in an animal model of glutaric aciduria type I.
    Sauer SW; Opp S; Komatsuzaki S; Blank AE; Mittelbronn M; Burgard P; Koeller DM; Okun JG; Kölker S
    Biochim Biophys Acta; 2015 May; 1852(5):768-77. PubMed ID: 25558815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutaric aciduria type I: outcome of patients with early- versus late-diagnosis.
    Couce ML; López-Suárez O; Bóveda MD; Castiñeiras DE; Cocho JA; García-Villoria J; Castro-Gago M; Fraga JM; Ribes A
    Eur J Paediatr Neurol; 2013 Jul; 17(4):383-9. PubMed ID: 23395213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited Disorders of Lysine Metabolism: A Review.
    Bouchereau J; Schiff M
    J Nutr; 2020 Oct; 150(Suppl 1):2556S-2560S. PubMed ID: 33000154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated glutaric acid levels in Dhtkd1-/Gcdh- double knockout mice challenge our current understanding of lysine metabolism.
    Biagosch C; Ediga RD; Hensler SV; Faerberboeck M; Kuehn R; Wurst W; Meitinger T; Kölker S; Sauer S; Prokisch H
    Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2220-2228. PubMed ID: 28545977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glutaric aciduria type I: an organic acidemia without acidosis with severe movement disorders].
    Prats Viñas J
    Neurologia; 2001 Oct; 16(8):337-41. PubMed ID: 11738010
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and mutational spectra of 23 Chinese patients with glutaric aciduria type 1.
    Wang Q; Li X; Ding Y; Liu Y; Song J; Yang Y
    Brain Dev; 2014 Oct; 36(9):813-22. PubMed ID: 24332224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The first knock-in rat model for glutaric aciduria type I allows further insights into pathophysiology in brain and periphery.
    Gonzalez Melo M; Remacle N; Cudré-Cung HP; Roux C; Poms M; Cudalbu C; Barroso M; Gersting SW; Feichtinger RG; Mayr JA; Costanzo M; Caterino M; Ruoppolo M; Rüfenacht V; Häberle J; Braissant O; Ballhausen D
    Mol Genet Metab; 2021 Jun; 133(2):157-181. PubMed ID: 33965309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative damage in glutaric aciduria type I patients and the protective effects of l-carnitine treatment.
    Guerreiro G; Faverzani J; Jacques CED; Marchetti DP; Sitta A; de Moura Coelho D; Kayser A; Kok F; Athayde L; Manfredini V; Wajner M; Vargas CR
    J Cell Biochem; 2018 Dec; 119(12):10021-10032. PubMed ID: 30129250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutaric acidemia type 1: outcomes before and after expanded newborn screening.
    Viau K; Ernst SL; Vanzo RJ; Botto LD; Pasquali M; Longo N
    Mol Genet Metab; 2012 Aug; 106(4):430-8. PubMed ID: 22728054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of BDNF and cathepsin-d as possible peripheral markers of neurodegeneration in plasma of patients with glutaric acidemia type I.
    Guerreiro G; Diaz Jaques CE; Wajner M; Vargas CR
    Int J Dev Neurosci; 2020 Feb; 80(1):42-49. PubMed ID: 31910296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.